| Relevance of sphingolipids in the pleiotropic protective effects of high-density lipoproteins. | |
| | |
MedLine Citation:
|
PMID: 20196741 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Atherosclerosis is the major cause of cardiovascular morbidity and mortality. A multitude of pro-atherogenic mediators are known liable for the initiation and progression of atherogenic vascular lesions. Only few endogenous molecules are known so far with cardiovascular protective properties, whereas high-density lipoprotein (HDL) is one of the most important. Beside cholesterol efflux, many pleiotropic cell-mediated functions of HDL are known so far. HDL is a spherical particle that contains different proteins and lipids. Especially sphingolipids, like sphingosine-1-phosphate (S1P), has gained great attention. The HDL associated S1P seems to be responsible for many of the pleiotropic effects of HDL by activating special S1P receptors. This review focuses on HDL associated sphingolipids as mediators of known protective pleiotropic effects of HDL and their possible therapeutic relevance. |
| | |
Authors:
|
Markus Tölle; Mirjam Schuchardt; Markus van der Giet |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current pharmaceutical design Volume: 16 ISSN: 1873-4286 ISO Abbreviation: Curr. Pharm. Des. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-05-27 Completed Date: 2010-08-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9602487 Medline TA: Curr Pharm Des Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 1468-79 Citation Subset: IM |
Affiliation:
|
Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Medizinische Klinik mit Schwerpunkt Nephrologie, Hindenburgdamm 30, D-12203 Berlin, Germany. markus.toelle@charite.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Apoptosis Atherosclerosis / prevention & control* Cell Adhesion Humans Lipoproteins, HDL / metabolism* Lysophospholipids / metabolism Neovascularization, Pathologic / prevention & control Receptors, Lysosphingolipid / metabolism Sphingolipids / metabolism* Sphingosine / analogs & derivatives, metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Lipoproteins, HDL; 0/Lysophospholipids; 0/Receptors, Lysosphingolipid; 0/Sphingolipids; 123-78-4/Sphingosine; 26993-30-6/sphingosine 1-phosphate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: High-Density Lipoprotein-Mediated Anti-Atherosclerotic and Endothelial-Protective Effects: A Potenti...
Next Document: Functional Interactions between Endogenous Cannabinoid and Opioid Systems: Focus on Alcohol, Genetic...